JADDP 2014-007 JADA vs J-4069

30 Jan 2015

In December 2014 the Japan Anti-Doping Agency (JADA) has reported an anti-doping rule violation against the Athlete J-4069 (the Athlete) after his sample tested positive for the prohibited substance tulobuterol. After notification a provisional suspension was ordered and the Athlete filed a statement in his defence.

The Athlete submitted, sustained by his doctor and medical record, that he suffered from asthma and had used Hokunalin medication which was prescribed for the treatment of his son’s bronchitis.
The Athlete took the medication a few days before the competition as an emergency measure due to his aggravating asthma before he received medical treatment in the hospital by his family doctor.

The Panel accepts the Athlete’s statement and concludes that he was carelessly with the use of the Hokunalin medication as emergency measure. Considering the circumstances the Japan Anti-Doping Disciplinary Panel decides on 30 January 2015 to impose a 3 month period of ineligibility on the Athlete starting on the date of the provisional suspension, i.e. on 17 December 2014.

JADDP 2014-005 JADA vs J-4068

4 Dec 2014

In October 2014 the Japan Anti-Doping Agency (JADA) has reported an anti-doping rule violation against the Athlete J-4068 (the Athlete) after her sample tested positive for the prohibited substance methyltestosterone. After notification a provisional suspension was ordered. The Athlete filed a statement in her defence defence and she was heard for the Japan Anti-Doping Disciplinary Panel.

The Athlete stated that she had used a medication for her stomach provided by her trainer in the week before she was tested. However by mistake he gave her stanozolol pills which he used. JADA reported that the Athlete’s sample tested positive for methyltestosterone and not for stanozolol.

The Panel dismissed the Athlete’s statement and concludes that the Athlete has been significant negligent without grounds for reduction of the period of ineligibility.
Therefore the Japan Anti-Doping Disciplinary Panel decides on 4 december 2014 to impose a 2 year period of ineglibility on the Athlete starting in the date of the provisional hearing, i.e. on 12 November 2014.

JADDP 2014-002 JADA vs J-4067

5 Jul 2014

In June 2014 the Japan Anti-Doping Agency (JADA) has reported an anti-doping rule violation against the Athlete J-4067 (the Athlete) after his sample tested positive for the prohibited substance methylephedrine.
After notification a provisional suspension was ordered and the Athlete filed a statement in his defence.

The Athlete submitted that he had used an over the counter cold medication a week before the competition and without intention to enhance his performance. The Panel concludes that the Athlete’s acted with a certain level of negligence due to he failed to check the ingredients of the medication before using.
Considering the circumstances the Japan Anti-Doping Disciplinary Panel decides on 5 July 2014 to impose a 3 month period of ineligibility on the Athlete starting on the date of the provisional suspension, i.e. on 18 June 2014.

JADDP 2014-001 JADA vs J-4066

23 Jul 2014

In June 2014 the Japan Anti-Doping Agency (JADA) has reported an anti-doping rule violation against the Athlete J-4066 (the Athlete) after her sample tested positive for the prohibited substance canrenone.
After notification a provisional suspension was ordered and the Athlete filed a statement in her defence.

The Athlete submitted, sustained by her doctor and medical record, that she had used a prescribed medication for her skin condition without intention to enhance her performance or to mask the use of a prohibited substance.
The Panel concludes that the Athlete’s acted with a certain level of negligence due to she failed to check the ingredients of the medication before using and did not mention to her doctor that she was an athlete.
Considering the circumstances the Japan Anti-Doping Disciplinary Panel decides on 23 July 2014 to impose a 3 month period of ineligibility on the Athlete starting on the date of the provisional suspension, i.e. on 16 June 2014.

iNADO - NADO call to IOC for Ban of the Russian Delegations from the Rio Olympics and Paralympics

20 Jul 2016

NADO call for Ban of the Russian Delegations from the Rio Olympics and Paralympics : submission / Institute of National Anti-Doping Organisations (iNADO). - Bonn : iNADO, 2016


As a consequence of the damning findings of the Report into State-sponsored interference in Anti-Doping released on 18 July 2016 by Professor Richard McLaren, the Russian Delegation should be prohibited from participating at the Olympic and Paralympic Games in Rio de Janerio.

14 National Anti-Doping Organisations (NADO's) and the Institute of National Anti-Doping Organisations (iNADO) issued that statement in response to the release on 18 July 2016 of Professor Richard McLaren’s Report into Russian Government tampering with anti-doping efforts in Russia. The McLaren Report was a disappointing and shocking glimpse into a massive conspiracy against the clean athletes of the world. In making that statement, iNADO supports the position taken by the World Anti-Doping Agency (WADA).

Autologous Blood Transfusion in Sports : Emerging Biomarkers

21 May 2016

Autologous Blood Transfusion in Sports: Emerging Biomarkers / Olivier Salamin, Sara De Angelis, Jean-Daniel Tissot, Martial Saugy Nicolas Leuenberger . – (Transfusion Medicine Reviews 30 (2016) 3 (July) : p. 109-115).

  • PMID: 27260108.
  • DOI: http://dx.doi.org/10.1016/j.tmrv.2016.05.007


Abstract

Despite being prohibited by the World Anti-Doping Agency, blood doping through erythropoietin injection or blood transfusion is frequently used by athletes to increase oxygen delivery to muscles and enhance performance. In contrast with allogeneic blood transfusion and erythropoietic stimulants, there is presently no direct method of detection for autologous blood transfusion (ABT) doping. Blood reinfusion is currently monitored with individual follow-up of hematological variables via the athlete biological passport, which requires further improvement. Microdosage is undetectable, and suspicious profiles in athletes are often attributed to exposure to altitude, heat stress, or illness. Additional indirect biomarkers may increase the sensitivity and specificity of the longitudinal approach. The emergence of "-omics" strategies provides new opportunities to discover biomarkers for the indirect detection of ABT. With the development of direct quantitative methods, transcriptomics based on microRNA or messenger RNA expression is a promising approach. Because blood donation and blood reinfusion alter iron metabolism, quantification of proteins involved in metal metabolism, such as hepcidin, may be applied in an "ironomics" strategy to improve the detection of ABT. As red blood cell (RBC) storage triggers changes in membrane proteins, proteomic methods have the potential to identify the presence of stored RBCs in blood. Alternatively, urine matrix can be used for the quantification of the plasticizer di(2-ethyhexyl)phthalate and its metabolites that originate from blood storage bags, suggesting recent blood transfusion, and have an important degree of sensitivity and specificity. This review proposes that various indirect biomarkers should be applied in combination with mathematical approaches for longitudinal monitoring aimed at improving ABT detection.

Content:

- The ABP and Hematological Markers
- Transcriptomics
- Plasticizers in Urine Matrix
- Study of Storage Lesions Using Proteomics
- Combination of Biomarkers
- Conclusion
- Conflict of interest
- Acknowledgments
- References

Doping anno 1996

1 Nov 1996

Doping anno 1996 / F. Hartgens . – (Geneemiddelenbulletin 30 (1996) 11 (November) : p. 125-132)

The article is intended for (general) physicians and pharmacists. It discusses the historical backgrounds of doping, the definition of doping, and the Prohibited List of the IOC. The substances and methods on this list are discussed for their characteristics and side-effects.



Contents (in Dutch):

Inleiding
Historische achtergronden
Definities van doping
De lijst van dopinggeduide middelen en methoden ‘de dopinglijst’
I Dopinggroepen
- A Stimulantia
- A.1. Amfetaminen en verwante verbindingen inclusief eetlustremmende middelen
- A.2. Overige psychostimulantia
- A.3. Sympathicomimetica
- B. Narcotische analgetica
- C. Anabole middelen
- C.I. Androgene-anabole steroïden
- C.2 β₂-Sympathicomimetica
- D. Diuretica
- E. Peptide en glycoproteïne hormonen en analoga
- E.1. Chorlongonadotrofien (HCG, humaan choriongonadotrofine)
- E.2. Corticotropine (ACTH)
- E.3 Groeihormoon (HGH, somatropine)
- E.4 Erytropoëtine (EPO)
II Dopingmethoden
- A. Bloeddoping
- B. Farmacologische, chemische en fysische manipulatie
III Groepen van middelen die aan bepaalde restricties zijn gebonden
- A. Alcohol
- B. Marihuana
- C. Locale anaesthetica
- D. Corticosteroïden
- E. β-Blokkers
De Sporter en de arts
Conclusies en samenvatting

Doping test reveals high concentrations of salbutamol in a Swiss track and field athlete

1 Sep 2004

Doping test reveals high concentrations of salbutamol in a Swiss track and field athlete / Carine Schweizer, Martial Saugy, Matthias Kamber. – (Clinical journal of sport medicine 14 (2004) 5 (Sep) : p. 312-315) ; PMID: 15377972

Beta-2 agonists are on the list of prohibited substances in sport. Salbutamol by inhalation is permitted to treat allergic asthma, and/or exercise-induced asthma or exercise-induced bronchoconstriction. If the level of salbutamol in urine exceeds 1000 ng/mL, the result is considered as a doping violation with an anabolic steroid. We report a case of a track and field athlete who tested well above this limit during a competition. He had a valid therapeutic use exemption for the use of salbutamol by inhalation and he claimed that he never used salbutamol orally. Further studies under controlled application by inhalation showed that this limit was exceeded. We propose that sanctioning bodies in sport should consider this possibility before taking into account a two-year ban for the use of an anabolic steroid.

Content:

Case Report
- History
- Salbutamol Excretion Study
- Analytical Details
- Discussion

Doping, a state of affairs

1 Jul 2016

Doping, a state of affairs / O. de Hon, F. Stoel. – (Geneesmiddelenbulletin 50 (2016) 7 (Juli) : p. 75-83)

This article is an update of a 1996-article, intended for physicians and pharmacists. It discusses in detail the scientific proof of the performance enhancing capacities of prohibited substances, as well as their side effects.

Contents (in Dutch):


Doping, een stand van zaken / O. de Hon, F. Stoel. – (Geneesmiddelenbulletin 50 (2016) 7 (Juli) : p. 75-83)

In een jaar waarin de zomer wordt beheerst door sportevenementen, zoals de Tour de France en de Olympische Spelen, is de kans groot dat op de sportpagina’s van de diverse dagbladen ook veel aandacht zal worden besteed aan doping en dopinggevallen. Dit artikel geeft een overzicht van het actuele wetenschappelijke bewijs voor de werkzaamheid van doping.

Inhoud:

- Inleiding
- Definitie, dopinglijst en controle, epidemiologie van het gebruik en de rol van de zorgverlener
- Definitie
- Dopinglijst en controle
- Epidemiologie van het gebruik
- Rol van de zorgverlener
- De dopinglijst en haar achtergronden
- Algemeen
- Wetenschappelijk onderzoek
I. Verboden middelen en methoden
- Androgene anabole steroïden
o Beoogde werking
o Bijwerkingen
- Overige anabole middelen
- Erytropoëtische groeifactoren
o Beoogde werking
o Bijwerkingen
- Groeihormonen
o Beoogde werking
o Bijwerkingen
- Overige peptide hormonen en aanverwante middelen
- β₂-Sympathicomimetica
o Beoogde werking
o Bijwerkingen
- Hormoon- en metabole modulatoren
- Diuretica
o Beoogde werking
o Bijwerkingen
- Maskerende middelen
II. In wedstrijdverband verboden middelen
- Stimulantia
o Beoogde werking
o Bijwerkingen
- Opiöden
- Cannabinoïden
- Glucocorticosteroïden
III. Middelen die bij bepaalde sporten verboden zijn
- Alcohol
- β-Sympathicolytica
o Beoogde werking
o Bijwerkingen

CAS 2015_A_4233 WADA vs Matin Johnsrud Sundby & FIS

11 Jul 2016

CAS 2015/A/4233 World Anti-Doping Agency (WADA) v. Martin Johnsrud Sundby & Fédération Internationale de Ski (FIS)

Skiing (cross-country skiing)
Doping (salbutamol)
Principles of “tempus regit actum” and “lex mitior”
Inhalation of a prohibited substance in excess of the “use threshold” and without a TUE
Definition of “inhaled”
Principle of the individualisation of the sanction
Determination of the category of fault in which a particular case might fall
Automatic disqualification

1. The applicable substantive rules must be identified by reference to the principle “tempus regit actum”: in order to determine whether an act constitutes a disciplinary infringement, a CAS panel applies the law in force at the time the act was committed. In other words, new regulations, unless they are more favourable for the athlete in accordance with the lex mitior principle, do not apply retroactively to facts that occurred prior to their entry into force, but only for the future.

2. Under the Prohibited Lists, the general rule is that all Beta-2 Agonists are prohibited, unless covered by an exception. As a matter of principle, an exception to a general rule is to be narrowly construed. With regard to salbutamol, only use by inhalation is permitted. The use of inhalation to administer salbutamol (as distinct from administration by ingestion or injection) is a necessary but not a sufficient element to engage the exception. It is also necessary not to exceed the “use threshold” which refers to the maximum dose that can be taken by inhalation, i.e. the “labelled” or “nominal” dose. Considering that the athlete in question used a nebulizer to inhale salbutamol and that the smallest dose available by nebulizer exceeds the “use threshold” for said substance, the athlete’s fault lies in failing to request a Therapeutic Use Exemption (TUE), the grant of which would have enabled him to compete without breach of the rules.

3. The epithet “inhaled” is deployed in the context of the exception to the prohibition of all Beta-2 Agonists to identify the mechanics of administration. In other words, it is meant to distinguish “inhalation” from “ingestion” or “injection” (by both of which means salbutamol can be administered), such that only use by inhalation is permitted. The epithet “inhaled” does not serve any further or alternative purpose; it cannot bear two meanings simultaneously or describe at one and the same time the stage of administration as well as the mechanics of administration. Such an interpretation would, in the absence of express indication to that effect, be inconsistent with ordinary rules of construction, including the principle of narrow interpretation of exceptions. It follows that the expression “therapeutic inhaled dose” only describes the mechanics of administration.

4. Although consistency of sanctions is a virtue, correctness remains a higher one: otherwise unduly lenient (or, indeed, unduly severe) sanctions may set a wrong benchmark inimical to the interests of sport. Therefore, even if precedents in terms of the approach in principle may provide helpful guidance, each case must be decided on its own facts.

5. According to CAS jurisprudence, in order to determine into which category of fault a particular case might fall, it is helpful to consider both the objective and subjective level of fault. The objective element describes what standard of care could have been expected from a reasonable person in the athlete’s situation. The subjective element describes what could have been expected from that particular athlete, in light of his personal capacities. The objective element should be foremost in determining into which of the three relevant categories of degree of fault (significant, normal, light) a particular case falls. The subjective element can then be used to move a particular athlete up or down within that category.

6. Article 9 of the FIS ADR (corresponding to Article 9 of the WADC) leaves no discretion to the relevant disciplinary body (or to a CAS panel): the results achieved in the given competition shall always be disqualified. This conclusion follows, as an unavoidable consequence, the finding of an anti-doping rule violation, without any possibility for the hearing body to adopt a decision not imposing it, even in those exceptional cases where no sanction is inflicted, because the athlete bears “No Fault or Negligence”. In other word, the automatic disqualification operates as a matter of fairness to all other athletes.


This case is about an athlete who took, upon medical advice, a medicine in a dosage leading to the adverse analytical findings in the samples he provided. The question to be decided concerns in essence whether such dosage is or is not allowed by the applicable anti-doping rules, adopted by FIS on the basis of the World Anti-Doping Code (WADC) and the consequences of such finding. It was not suggested by WADA (or by FIS) that the Athlete intentionally cheated or intentionally broke the rules and then tried to defend deliberate doping with spurious medical or other justifications. As is well known, however, the anti-doping rules require strict observance: hence the claim brought against the Athlete and the appeal heard by the CAS Panel.

In January 2015 the Fédération Internationale de Ski (FIS) has reported two anti-doping rule violations against the Norwegian Athlete Matin Johnsrud Sundby after his samples, provided in December 2014 and in January 2015, tested positive for salbutamol in a concentration above the WADA threshold (1000 ng/mL).

After notification the Athlete submitted in his defence that since December 2014 he had been in a state of airway obstruction with the use of more intensive anti-asthmatic medication than usual. The Athlete’s team doctor confirmed that during that period the Athlete suffered more airway obstructions with worsening respiratory symptoms and use of medication during the competitions when he provided a sample.

FIS accepted in February 2015 the filed statements and advised to the Norwegian Ski Federation (NSF) that no provisional suspension would be imposed.
The Athlete underwent two pharmacokinetic studies in April and May 2015 and deliberations followed between experts, FIS and WADA about the reported results and the maximum allowed dose of inhaled salbutamol administered by nebulizer or any onther inhalation method.

On 4 September 2015 the FIS Doping Panel decided that the abnormal results of the analyses of the provided samples do not constitute an anti-doping rule violation and no further consequences shall apply to the Athlete. The FIS Doping Panel notes that it is not in the position to determine what constitutes an accepted dose of “inhaled salbutamol” and invites WADA to further specify how Section S.3 of the Prohibited List must be interpreted and to clarify how to determine the maximum doses for inhalation.

Hereafter in October 2015 WADA appealed the FIS Doping Panel decision of 4 September 2015 with the Court of Arbitration for Sport (CAS). WADA requested the CAS Panel to set aside the FIS Doping Panel decision and to impose a reprimand (and no period of ineligibility) or a period of ineligibility up to a maximum of two years.

Without a valid TUE to cover the use of salbutamol the CAS Panel finds that the Athlete committed an anti-doping rule violation under the FID ADR.
Having regard to all of the circumstances of the case, that is in light of its objective and subjective elements, and especially the fact that there was medical justification for the Athlete’s use of salbutamol, the Panel comes to the conclusion that the Athlete’s degree of fault was light and accordingly warrants the imposition of a sanction shorter than the standard measure for such cases, in this instance of two months ineligibility.

Therefore the Court of Arbitration for Sport decides on 11 July 2016 that:

1.) The appeal filed on 12 October 2015 by the World Anti-Doping Agency (WADA) against the decision taken on 4 September 2015 by the Doping Panel of the Fédération International de Ski (FIS) is upheld.
2.) The decision taken on 4 September 2015 by the Doping Panel of the Fédération International de Ski (FIS) is set aside.
3.) Martin Johnsrud Sundby has violated Article 2.1 of the applicable FIS anti-doping rules and is sanctioned with a period of ineligibility of two months starting from the date of this award. The results obtained by Mr Martin Johnsrud Sundby on 13 December 2014 in Davos (Switzerland) and on 8 January 2015 in Toblach (Italy) are disqualified.
4.) The present arbitration procedure shall be free, except for the CAS Court Office fee of CHF 1,000 (one thousand Swiss francs), which has already been paid by the Appellants and is retained by the CAS.
5.) Each party shall bear the costs it has sustained in connection with these arbitration proceedings.
6.) All other motions or prayers for relief are dismissed.

Category
  • Legal Source
  • Education
  • Science
  • Statistics
  • History
Country & language
  • Country
  • Language
Other filters
  • ADRV
  • Legal Terms
  • Sport/IFs
  • Other organisations
  • Laboratories
  • Analytical aspects
  • Doping classes
  • Substances
  • Medical terms
  • Various
  • Version
  • Document category
  • Document type
Publication period
Origin